メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の幹細胞技術・適応市場:2018年〜2028年 - 癌・心血管・中枢神経系・その他の疾患領域および非治療用途

Global Stem Cell Technologies and Applications Market 2018-2028: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications

発行 Visiongain Ltd 商品コード 203833
出版日 ページ情報 英文 284 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=150.61円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界の幹細胞技術・適応市場:2018年〜2028年 - 癌・心血管・中枢神経系・その他の疾患領域および非治療用途 Global Stem Cell Technologies and Applications Market 2018-2028: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications
出版日: 2018年03月02日 ページ情報: 英文 284 Pages
概要

世界の幹細胞技術・適応市場は、2017年〜2028年のCAGR (複合年間成長率) で、11.5%の成長が予測されています。

当レポートでは、世界の幹細胞技術・適応市場について調査分析し、市場予測、二次市場予測、主要製品の収益予測、有望なパイプライン分析、規制環境と発展、市場の促進要因・抑制要因、影響要因などについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 幹細胞技術・適応とは

  • 幹細胞とは、特徴の定義
  • 幹細胞研究のタイムライン
  • ES細胞の登場
  • 幹細胞の分類:効能別
  • 幹細胞の主な種類とその特性
  • iPS細胞:ES細胞のメリット、デメリット
  • 単為発生幹細胞:科学的背景
  • 自家 vs. 同種幹細胞
  • 治験のフェーズ
  • レポートの範囲

第3章 国際的開発と幹細胞の規制環境

  • 米国の規制環境
  • 欧州の規制環境
  • 日本の規制環境
  • 韓国の規制環境
  • 中国の規制環境
  • イスラエルの規制環境
  • インドの規制環境

第4章 幹細胞技術・適応:世界市場

  • 幹細胞の治療適応 vs. 非治療適応
  • 世界市場の地域別
  • 市場区分
  • 幹細胞技術・適応市場:予測
  • 幹細胞技術・適応市場:予測 (セグメント別)
  • セグメント別の市場シェアの変化
  • 幹細胞技術・適応市場:促進要因・抑制要因

第5章 幹細胞癌治療セグメント

  • 幹細胞癌治療:概要と現状
  • 幹細胞癌治療:市場予測
  • 造血幹細胞移植 (HSCT)
  • 処置から製品へ:臍帯血幹細胞の承認
  • 幹細胞癌治療パイプライン
  • 幹細胞癌治療:促進要因・抑制要因

第6章 幹細胞心血管治療セグメント

  • 幹細胞心血管治療:概要と現状
  • 幹細胞心血管治療:市場予測
  • 心血管疾患は世界の医薬品市場の大部分を占める
  • 心血管疾患の幹細胞研究の状況
  • 心臓における幹細胞の神秘的な効果
  • 幹細胞心疾患治療の上市薬
  • 幹細胞心疾患治療パイプライン
  • 幹細胞心疾患治療:促進要因・抑制要因

第7章 幹細胞中枢神経系 (CNS) 治療セグメント

  • 幹細胞CNS治療:概要と現状
  • 幹細胞CNS治療:市場予測
  • CNS疾患の幹細胞研究の状況
  • 特定のCNS疾患における進歩
  • 数十億米ドル規模の市場
  • 幹細胞CNS治療パイプライン
  • 幹細胞CNS治療:促進要因・抑制要因

第8章 その他の疾患における幹細胞治療セグメント

  • その他の疾患における幹細胞治療:概要と現状
  • その他の疾患における幹細胞治療:市場予測
  • その他の疾患における幹細胞治療:上市薬
  • その他の疾患における幹細胞治療:研究分野
  • その他の疾患における幹細胞治療:パイプライン
  • 遺伝子組み換え幹細胞治療

第9章 幹細胞非治療適応

  • 幹細胞非治療適応:概要と現状
  • 幹細胞非治療適応:市場予測
  • 幹細胞バンキング:世界の需要増
  • 幹細胞供給・加工:iPS細胞
  • 幹細胞ベースアッセイ:大きな可能性
  • 研究・試薬・その他
  • 促進要因・抑制要因

第10章 幹細胞技術・適応市場の定性分析

  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • 社会的要因
  • 技術的要因
  • 経済的要因
  • 政治的要因

第11章 結論

目次
Product Code: PHA0291

The global stem cell technologies and applications market is estimated to have reached $12,040 million and is expected to grow at a CAGR of 13.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 11.5% from 2017 to 2028.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 284-page report you will receive 114 charts- all unavailable elsewhere.

The 284-page report provides clear detailed insight into the global stem cell technologies and applications market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

image1

Report Scope

  • Global Stem Cell Technologies and Applications Market forecasts from 2018-2028
  • Global Stem Cell Technologies and Applications submarket forecasts from 2018-2028:
  • Cancer treatment
  • Cardiovascular therapy
  • CNS
  • Other therapies
  • Non-therapeutic applications
  • Individual revenue forecast to 2028 for selected top products:
  • MSC-100-IV (Mesoblast)
  • Hearticellgram-AMI (Pharmicell)
  • CardioRel (Reliance Life Sciences)
  • Osteocel Plus (NuVasive)
  • Trinity Evolution and Elite (Orthofix)
  • CARTISTEM (MEDIPOST)
  • Analysis of the most promising pipeline therapies in each therapeutic segment
  • Discussion on regulatory environments and developments in the US, Japan, Europe and other leading countries
  • Analysis of what drives and restrains the market
  • This study also discusses other influences on that field, including these:
  • Haematopoietic stem cell transplantation (HSCT)
  • Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
  • Uses for umbilical cord blood and related technologies, including cellular and blood banking
  • Agents for osteogenesis and treating autoimmune conditions
  • Applications in cell-based assays, diagnostics and drug development.

Visiongain's study is intended for anyone requiring commercial analyses for the Global Stem Cell Technologies and Applications Market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Stem Cell Technologies and Applications Market Overview
  • 1.2 Why you should Read This Report
  • 1.3 How this Report Delivers
  • 1.4 Key Questions Answered by This Report
  • 1.5 Who is this Report for?
  • 1.6 Research and Analysis Methods
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. Introduction to Stem Cell Technologies and Applications

  • 2.1 What are Stem Cells? Defining Characteristics
  • 2.2 Timeline of Stem Cell Research
  • 2.3 Embryonic Stem Cells (ESCs) Enter the Picture
  • 2.4 Classifying Stem Cells by Potency
    • 2.4.1 Post Fertilisation and Germ Layers
  • 2.5 The Main Types of Stem Cells and Their Properties
  • 2.6 iPSCs: The Benefits of ESCs, but Without the Downsides?
    • 2.6.1 CIRM hPSC Repository Launches 300 iPSC Lines
  • 2.7 Parthenogenetic Stem Cells: Scientific Background
    • 2.7.1 Are they Ethical Alternatives to ESCs? What are the Commercial Applications?
  • 2.8 Autologous Versus Allogeneic Stem Cells
    • 2.8.1 Are Universal Stem Cell Products Possible?
  • 2.9 Phases of Clinical Trials
  • 2.10 Scope of this Report

3. International Developments and Stem Cell Regulatory Environments

  • 3.1 Regulatory Environment in the US
    • 3.1.1 Dynamic Biotechnology Sector and Liberal Stance on Patents
    • 3.1.2 Understanding 'Homologous' Use
    • 3.1.3 Controversy Surrounding ESC Research
    • 3.1.4 NIH ESC Stem Cell Registry: Has Made Good Progress, but not enough for its Critics
    • 3.1.5 CIRM and NIH Stem Cell Funding into Vaious Channels
    • 3.1.6 FDA vs Regenerative Sciences
    • 3.1.7 Are Stem Cells Clinics the 'Wild West' of Medicine?
    • 3.1.8 Stem Cell Clinics Using Loopholes to Avoid Oversight?
    • 3.1.9 FDA Releases Three New Draft Guidances, but is it Doing Enough?
  • 3.2 Regulatory Environment in Europe
    • 3.2.1 Unified Overarching System of Regulation Across EU
    • 3.2.2 Difference between EU Member States Regarding hESC Research
    • 3.2.3 European Court of Justice Performs an U-Turn and Clears Path towards Stem Cell Patents
    • 3.2.4 The UK: A Leader in European Stem Cell Research
  • 3.3 Regulatory Environment in Japan
    • 3.3.1 Liberal Stance on hESC but with Excessive Bureaucracy?
    • 3.3.2 Japan: A Pioneer in iPSC Research, Although First In-Human Trial has been suspended
    • 3.3.3 The STAP Cell Events: Excitement Dashed
    • 3.3.3.1 Riken Concludes Investigation
    • 3.3.4 Government Committed to Regenerative Medicines and iPSC Research
    • 3.3.5 Japan Becomes Very Attractive Market for Stem Cell Companies due to Favourable Regulatory Changes
  • 3.4 Regulatory Environment in South Korea
    • 3.4.1 Highs and Lows with Regard to hESC Research
    • 3.4.2 Regulators are Quick to Approve Therapies, Although this has Drawn Criticism
    • 3.4.3 Tracheal Transplant Patient Dies
    • 3.4.4 New changes a requirement for the current research and development in HESC
  • 3.5 Chinese Regulatory Environment
    • 3.5.1 Liberal Regulation on Stem Cells and Very High Number of Stem Cell Clinical Trials Taking Place in the Country
    • 3.5.2 Stem Cell Medical Tourism Very Popular
    • 3.5.3 CFDA Releases New Stem Cell Draft Guidance
  • 3.6 Israel Regulatory Environment: A Strong Presence in Stem Cell Research
  • 3.7 Indian Regulatory Environment: Emerging Stem Cell Industry - in Need of more Regulation?

4. Stem Cell Technologies and Applications: World Market 2018-2028

  • 4.1 Therapeutic Applications versus Non-Therapeutic Applications of Stem Cells
  • 4.2 Regional Breakdown of the World Market
  • 4.3 Market Segmentation
  • 4.4 Stem Cell Technologies and Applications Market: Forecast 2017-2028
  • 4.5 Stem Cell Technologies and Applications Market: Forecast by Segment 2017-2028
  • 4.6 How Will Segmental Market Shares Change to 2028?
    • 4.6.1 Which Segments will Grow the Most?
  • 4.7 Stem Cell Technologies and Applications Market: Drivers and Restraints

5. Stem Cell Cancer Therapeutics Segment 2018-2028

  • 5.1 Stem Cell Cancer Therapeutics: Overview and Current Status
  • 5.2 Stem Cell Cancer Therapeutics: Market Forecast 2018-2028
  • 5.3 Haematopoietic Stem Cell Transplantation (HCST)
    • 5.3.1 An Established Treatment for Haematological Cancers
    • 5.3.2 Autologous HSCT: Dominant Form of HSCT
    • 5.3.3 Autologous Versus Allogeneic HSCT: Advantages and Disadvantages
    • 5.3.4 GvHD: The Major Issue for HSCT
    • 5.3.5 Strengths and Weaknesses of the Three Major Sources of HSCs
    • 5.3.6 What is Cord Blood?
      • 5.3.6.1 Cord Blood Use is Rising in HSCT
    • 5.3.7 Number of HSCT Operations Performed Worldwide, Split by Autologous Versus Allogeneic HSCT, 2015-2017
    • 5.3.7.1 Numbers of HSCT Operations Performed in Europe, Split by Donor Type, 2011-2017
    • 5.3.8 HSCT Costs and Medicare Coverage
    • 5.3.9 The Indications which can be treated with HSCT: Haematological Malignancies are the Major Indications
    • 5.3.10 HSCT has the Potential to Address Multiple Cancers, which represent a $20bn+ Market
  • 5.4 From Procedures to Products: Cord Blood Stem Cell Approvals
    • 5.4.1 Hemacord (New York Blood Center): The First FDA-Approved Cord Blood Product
      • 5.4.1.1 Hemacord Awarded Prix Galien 'Best Biotechnology Product' Award
    • 5.4.2 HPC, Cord Blood (ClinImmune Labs / University of Colorado Blood Bank)
    • 5.4.3 Ducord (Duke University School of Medicine)
    • 5.4.4 Allocord (SSM Cardinal Glennon Children's Medical Center)
    • 5.4.5 HPC, Cord Blood BLA 125432 (LifeSouth Community Blood Centers)
    • 5.4.6 CLEVECORD
    • 5.4.7 HPC, Cord Blood (BLA 125585)
  • 5.5 Stem Cell Cancer Therapeutics Pipeline
    • 5.5.1 Agenmestencel-T (Apceth)
    • 5.5.2 CLT-008 and CLT-009 (Cellerant Therapeutics): Company Receives $47.5m Grant from US Government
    • 5.5.3 ProHema (Fate Therapeutics)
      • 5.5.3.1 ProTmune
    • 5.5.4 StemEx and NiCord (Gamida Cell)
      • 5.5.4.1 StemEx Shows Improved Survival at 100 Days - but FDA Wants Another Clinical Trial
      • 5.5.4.2 Copper Chelator Based Technology
      • 5.5.4.3 NiCord
      • 5.5.4.4 NiCord: The Company Aiming for a "Paradigm Shift" in Treatment Practice, Receives Orphan Drug Designation
      • 5.5.4.5 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
      • 5.5.4.6 NAM Technology Platform
      • 5.5.4.7 Novartis Chooses not to buy Gamida Cell
    • 5.5.5 MSC-100-IV (Previously Known as Prochymal) and Unnamed MPC-Expanded Cord Blood Product (Mesoblast)
      • 5.5.5.1 MSC-100-IV: World's First Approved Stem Cell Drug Outside of South Korea
      • 5.5.5.2 MSC-100-IV: Culture Expanded and Able to Treat GvHD
      • 5.5.5.3 An Important Role to Play in the Future of HSCT
      • 5.5.5.4 Wins Approval in Japan, through Partner JCR Pharmaceuticals, and Phase 3 Trial will Support US BLA
      • 5.5.5.5 MSC-100-IV / Temcell HS Injection Revenue Forecast 2017-2028
      • 5.5.5.6 MPC-Expanded Cord Blood Product in a Phase 3 Trial for Haematological Malignancies
    • 5.5.6 HSC835 (Novartis)
      • 5.5.6.1 Novartis Enters Partnership Agreement with Regenerex to Develop Novel Cell-Based Therapies
      • 5.5.6.2 Collaborations with Intellia Therapeutics and Caribou for CRISPR and HSCs
      • 5.5.6.3 Collaborations with Gamida Cell, Israel
    • 5.5.7 Ancillary Products for the HSCT Setting
    • 5.5.8 Targeting of Cancer Stem Cells (CSCs)
  • 5.6 Stem Cell Cancer Therapeutics: Drivers and Restraints 2018-2028

6. Stem Cell Cardiovascular Therapeutics Segment 2018-2028

  • 6.1 Stem Cell Cardiovascular Therapeutics: Overview and Current Status
  • 6.2 Stem Cell Cardiovascular Therapeutics: Market Forecast 2017-2028
  • 6.3 Cardiovascular Diseases Make up a Large part of the Global Pharmaceutical Market
    • 6.3.1 Stem Cell Treatments for Stroke: Touched Upon in This Chapter but mainly Covered under Central Nervous System Therapeutics
    • 6.3.2 Cardiovascular and Cerebrovascular Conditions are the World's Most Fatal Diseases
    • 6.3.3 AMI, CLI and Stroke: Major Ischemic Disease Targets
  • 6.4 The State of Stem Cell Research for Cardiovascular Diseases
    • 6.4.1 Practical Advantages to Choosing the Heart as a Target for Stem Cell R&D
    • 6.4.2 Defining Cardiovascular Stem Cells: Scientific Context
  • 6.5 The Mysterious Effects of Stem Cells in the Heart
    • 6.5.1 MSCs in the Heart: Evidence to Support their Use, as well as Doubts over their Efficacy
    • 6.5.2 Cardiosphere-Derived Cells, hESC-Derived Cardiomyocytes and C-kit Cells
  • 6.6 Stem Cell Cardiovascular Therapeutics on the Market
    • 6.6.1 Hearticellgram-AMI (Pharmicell)
      • 6.6.1.1 One of the First Approved Cardiovascular Stem Cell Treatments in the World
      • 6.6.1.2 Hearticellgram-AMI Sales Estimates 2014-2017
      • 6.6.1.3 Will Have Difficulty Getting Approved in Markets Outside of South Korea
      • 6.6.1.4 Hearticellgram-AMI Revenue Forecast 2018-2028
    • 6.6.2 CardioRel (Reliance Life Sciences)
      • 6.6.2.1 Available on the Indian Market, but Does Data Back it up?
      • 6.6.2.2 CardioRel Revenue Forecast 2018-2028
  • 6.7 Stem Cell Cardiovascular Therapeutics Pipeline
    • 6.7.1 Ixmyelocel-T (Vericel Corporation)
      • 6.7.1.1 Vericel Shifts Focus Away from CLI and Towards DCM
      • 6.7.1.2 Currently it has met Phase 2b endpoint, with a Possible Launch in 2019
    • 6.7.2 Alecmestencel-T (Apceth)
    • 6.7.3 Arteriocyte: Using its 'Magellan System' to Treat CLI
    • 6.7.4 MultiStem (Athersys) for Myocardial Infarction and Stroke
      • 6.7.4.1 Updates from Athersys Regarding Trial Status: Did MultiStem Fail in Stroke, or was it just Being Assessed in the Wrong Treatment Window?
    • 6.7.5 Baxter: Phase 3 CD34+ Stem Cell Therapy for Refractory Angina
    • 6.7.6 CardiAMP (BioCardia) for Heart Failure: Scheduled to Finally Begin Phase 3 in January 2017
    • 6.7.7 MyoCell (U.S. Stem Cell, Inc. - Formerly Bioheart): Autologous 'Muscle Stem Cell' Therapy
      • 6.7.7.1 MyoCell: Is the Company Still Trying to Secure Funds to Restart the Phase 2/3 MARVEL Trial?
      • 6.7.7.2 MyoCell: MIRROR Trial on Hold
      • 6.7.7.3 MyoCell SDF-1: Improved Version of MyoCell
      • 6.7.7.4 MyoCell SDF-1 Phase 1 Trial (Regen): Another Trial Put on Hold
    • 6.7.8 CAP-1001 and CAP-1002 (Carpricor): Cardiospehere-Derived Cells for Heart Repair
    • 6.7.9 Ceylad (Formerly Cardio3): Proprietary Cardiopoiesis Technology Platform - Can be Applied to Various Stem Cell Sources
      • 6.7.9.1 C-Cure: Stem Cell Therapy for the Treatment of Heart Failure
      • 6.7.9.2 C-Cure: Two Phase 3 Trials Under Way
    • 6.7.10 Mesoblast: Mesenchymal Precursor Cells for Heart Failure and Myocardial Infarction
      • 6.7.10.1 Rexlemestrocel-L for Congestive Heart Failure (CHF), Chief Executive Provides Update
      • 6.7.10.2 CEP-41750: Promising Phase 2 Results, More Effective in a Particular Subset of Heart Failure Patients?
      • 6.7.10.3 Phase 2 Trial of MPCs in Acute Myocardial Infarction
    • 6.7.11 Caladrius Biosciences: Will not Continue Development of CLBS10, the Company's Former Lead Candidate
      • 6.7.11.1 CLBS12 for CLI: Due to Start Phase 2 in Japan in January 2016
    • 6.7.12 Stemedica Cell Technologies: 'Ischaemic-Tolerant' Stem Cell Platform
      • 6.7.12.1 Trials in Myocardial Infarction and Stroke
    • 6.7.13 Gemacell and Cryocell (Human Stem Cells Institute): Awaiting Important Russian Legislation to be Passed before Development Can Continue
  • 6.8 Stem Cell Cardiovascular Therapeutics: Drivers and Restraints 2017-2028

7. Stem Cell Central Nervous System Therapeutics Segment 2018-2028

  • 7.1 Stem Cell Central Nervous System Therapeutics: Overview and Current Status
  • 7.2 Stem Cell Central Nervous System Therapeutics: Market Forecast 2018-2028
  • 7.3 The State of Stem Cell Research in CNS Diseases
    • 7.3.1 Stem Cells are the Best Hope for Many Serious CNS Conditions
    • 7.3.2 Awaiting a First Breakthrough Approval
    • 7.3.3 Human Neural Stem Cells (NSCs) Successfully Isolated
    • 7.3.4 NSCs Reach the Clinic without Serious Controversy
    • 7.3.5 CNS Disorders are a Major Focus for ESC Research
    • 7.3.6 MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
  • 7.4 Progress in Specific CNS Conditions
    • 7.4.1 HSCT in MS: Could 'Resetting' the Immune System Treat MS?
      • 7.4.1.1 Clinical Trials Involving HSCT in MS
      • 7.4.1.2 Barriers to Overcome Before HSCT Could Become an Established Therapy for MS
    • 7.4.2 ALS: Could this Rare Disease be the First Neurodegenerative Condition for Stem Cell Treatment?
    • 7.4.3 Parkinson's Disease: Field Recovering after Voluntary Moratorium on Stem Cell Research by Many Western Nations Ends
    • 7.4.4 Dry Age-Related Macular Degeneration: A Major Unmet Need
  • 7.5 Several Multi-Billion Dollar Markets are Open to Stem Cell Developers if they can Translate the Potential of Stem Cells into Therapies
  • 7.6 Stem Cell Central Nervous System Therapeutics Pipeline
    • 7.6.1 MA09-hRPE (Ocata Therapeutics): Stem Cells for Eye Diseases
      • 7.6.1.1 Orphan Drug Status in both the US and EU
      • 7.6.1.2 Current Clinical Trials in SMD
      • 7.6.1.3 Early Signs of Efficacy
      • 7.6.1.4 Has Moved into Phase 2 in AMD
    • 7.6.2 NurOwn (BrainStorm Cell Therapeutics): Neurotrophic Factor -Releasing Stem Cells for ALS
      • 7.6.2.1 Phase 2 Trial in 48 ALS Patients Underway
      • 7.6.2.2 Phase 2a Results Demonstrate "Statistically Significant Effect"
    • 7.6.3 International Stem Cell Corporation: Company Signals Intent to Start Phase 1/2a Study in PD Soon
    • 7.6.4 Neuralstem: Allogeneic NSCs for Synaptic Repair and Neuroprotection
      • 7.6.4.1 NSI-566 in ALS
      • 7.6.4.2 NSI-566 in ALS: Encouraging Data from Completed Phase 2 Trial
      • 7.6.4.3 NSI-566 for Chronic Spinal Cord Injury: Phase 1 Top-Line Data Expected Q4 2015
      • 7.6.4.4 NSI-566 for Ischaemic Stroke: Phase 1/2 Trials Underway in China
      • 7.6.4.5 Preclinical Investigation in 11 Other Indications
    • 7.6.5 PF-05206388 (Pfizer and the London Project to Cure Blindness): Finally Begins Phase 1Trial, with first Successful Surgery
    • 7.6.6 Q-Cells (Q Therapeutics): Phase 1/2 Trial Begins
    • 7.6.7 ReNeuron: CTX Neural Cell Line and its Advantages
      • 7.6.7.1 CTX for Stroke
      • 7.6.7.2 CTX for Stroke: Long-Term PISCES Study Shows Promising Results
      • 7.6.7.3 CTX for Stroke: Undergoing Phase 2, Using Highest Cell Dose from PISCES Study
    • 7.6.8 SB623 (SanBio): Enters Phase 2 for Stroke, as well as for Traumatic Brain Injury
    • 7.6.9 StemCells, Inc: A Leader in Neural Stem Cells
      • 7.6.9.1 HuCNS-SC for Pelizaeus-Merzbacher Disease: Undergoing Second Phase 1 Trial
      • 7.6.9.2 HuCNS-SC for NCL: Second Phase 1 Trial Withdrawn
      • 7.6.9.3 HuCNS-SC for Spinal Cord Injury: Phase 2
      • 7.6.9.4 HuCNS-SC for AMD: Top-Line Phase 1/2 Results Released
  • 7.7 Stem Cell Central Nervous System Therapeutics: Drivers and Restraints 2018-2028

8. Stem Cell Therapeutics in Other Disease Areas 2018-2028

  • 8.1 Stem Cell Therapeutics in Other Disease Areas: Overview and Current Status
  • 8.2 Stem Cell Therapeutics in Other Disease Areas: Market Forecast 2017-2028
  • 8.3 Stem Cell Therapeutics in Other Disease Areas: Therapies on the Market
    • 8.3.1 Osteocel Plus (NuVasive)
      • 8.3.1.1 Osteocel to Osteocel Plus: Passing Through Different Companies and Patent Disputes
      • 8.3.1.2 The Leading Stem Cell Orthobiologic
      • 8.3.1.3 Is it Better than Autograft?
      • 8.3.1.4 Osteocel Plus Revenue Forecast 2017-2028
    • 8.3.2 Trinity Evolution and Trinity Elite (Orthofix): Stem Cell Orthobiologics
      • 8.3.2.1 Positive Results from New Trial in Foot and Ankle Procedures
      • 8.3.2.2 Trinity Evolution and Elite Revenue 2010-2014
      • 8.3.2.3 Trinity Evolution and Elite Revenue Forecast 2016-2027
    • 8.3.3 CARTISTEM (MEDIPOST)
      • 8.3.3.1 CARTISTEM: The World's First Allogeneic Stem Cell Drug
      • 8.3.3.2 CARTISTEM: Latest Updates Includes Results from Phase 3 Trial, Initiation of Phase 1/2 Trial in the US
      • 8.3.3.3 CARTISTEM: Revenues 2013 - H1 2015
      • 8.3.3.4 CARTISTEM Revenue Forecast 2017-2028
    • 8.3.4 Allostem (Allosource)
    • 8.3.5 Map3 (RTI Surgical)
    • 8.3.6 ReliNethra for Ocular Surface Damage (Reliance Life Sciences)
    • 8.3.7 Cupistem (Anterogen)
  • 8.4 Stem Cell Therapeutics for Other Diseases: Research Areas
    • 8.4.1 HSCT for Orphan Diseases
    • 8.4.2 Potential for Genetically Modified Stem Cells for HIV and Other Diseases?
    • 8.4.3 Stem Cells Contribute to the Osteogenesis Process in Bone Repair
    • 8.4.4 Stem Cells Gaining Increasing Importance in Bone Graft Market, but whether these are True 'Stem Cell Products' is Debatable
    • 8.4.5 Stem Cells also have Potential in Autoimmune Disorders
    • 8.4.6 Potential Cure for Diabetes?
      • 8.4.6.1 Clinical Stage Programmes in Diabetes
    • 8.4.7 Stem Cells in Active Liver Repair
    • 8.4.8 Long-Term Possibilities
  • 8.5 Stem Cell Therapeutics in Other Disease Areas: Pipeline
    • 8.5.1 ALLO-ASC and ALLO-ASC-DFU (Anterogen)
    • 8.5.2 MultiStem (Athersys): Fails Phase 2 Ulcerative Colitis, Still Undergoing Phase 1 as Immunomodulation Therapy after Liver Transplantation
    • 8.5.3 BioTime: Multiple Subsidiaries Focused on Regenerative Medicine
      • 8.5.3.1 AST-OPC1 and AST-VAC2 (Asterias Biotherapeutics)
      • 8.5.3.2 OpRegen (Cell Cure Neurosciences)
      • 8.5.3.3 Other BioTime Subsidiaries Related to Stem Cells: OncoCyte, ReCyte, ESI Bio, LifeMap Sciences Etc.
    • 8.5.4 Calimmune: Dual Anti-HIV Gene Therapy via Stem Cells
    • 8.5.5 (PDA-001 and PDA-002) Celgene Corporation
    • 8.5.6 ReJoin (Cellular Biomedicine Group): Interim Results from the MSCs for Knee Osteoarthritis
    • 8.5.7 PNEUMOSTEM (MEDIPOST)
      • 8.5.7.1 NEUROSTEM (MEDIPOST): Undergoing Phase 1/2 Trial and Obtains Patents Around the Globe
    • 8.5.8 Translational Biosciences: Set Up for the Sole Purpose of Conduction Stem Cell Clinical Trials, Five Phase 1/2 Trials Ongoing
    • 8.5.9 Mesoblast: MPCs for Various Indications
      • 8.5.9.1 MPC-300-IV in Diabetes
      • 8.5.9.2 MPC-300-IV in Rheumatoid Arthritis
      • 8.5.9.3 MPC-06-ID in Chronic Back Pain, Enters Phase 3
    • 8.5.10 Pluristem Therapeutics: Uses PLX Cells to Secrete Therapeutic Proteins in Damaged Tissues
      • 8.5.10.1 PLX-PAD: Phase 2 for Intermittent Claudication
      • 8.5.10.2 PLX-PAD: Completes Phase 1/2 for Injured Gluteal Muscle
      • 8.5.10.3 PLX-R18: In Preclinical Development for ARS
    • 8.5.11 Regeneus: Adipose Derived MSC Therapies
      • 8.5.11.1 Progenza Undergoing Phase 1 Trial
    • 8.5.12 S-Evans Biosciences: Menstrual Stem Cells
    • 8.5.13 TiGenix: Expanded Adipose-Derived Stem Cell Therapies
      • 8.5.13.1 EASC Technology Platform
      • 8.5.13.2 Cx601: Meets Primary Endpoint in Phase 3 Trial
      • 8.5.13.3 The Road to Approval for Cx601 in Europe and the US
      • 8.5.13.4 Cx611 for Rheumatoid Arthritis and also Severe Sepsis
      • 8.5.13.5 Cx621 - Positive Results from Phase 1 Trial, but Development on Hold
      • 8.5.13.6 ChondroCelect Already on the Market - Although is More of a Cell Therapy Rather than a Stem Cell Therapy
    • 8.5.14 VC-01 (ViaCyte)
  • 8.6 Genetically Modified Stem Cell Therapies
    • 8.6.1 BluebirdBio: Gene-Modified HSCs for Orphan Diseases
    • 8.6.2 GSK: Stem Cell Gene Therapies for Rare Diseases, Including one which has been Submitted for Approval in Europe

9. Stem Cell Non-Therapeutic Applications 2018-2028

  • 9.1 Stem Cell Non-Therapeutic Applications: Overview and Current Status
  • 9.2 Stem Cell Non-Therapeutic Applications: Market Forecast 2017-2028
  • 9.3 Stem Cell Banking: Growing Demand Worldwide
    • 9.3.1 Impact of the current epidemic of Zika Virus and HIV in cord cell banking
    • 9.3.2 Is there a Need for Stem Cell Banking as a Form of 'Health Insurance'?
    • 9.3.3 Stem Cell Banking Companies in the US and Around the World
    • 9.3.4 Dental Stem Cell Banking: An Alternative to Cord Blood Banks?
  • 9.4 Stem Cell Supply and Processing: iPSCs are the New Driver
    • 9.4.1 Stem Cell Supply and Processing Companies
  • 9.5 Stem Cell-Based Assays: Major Potential for Preclinical Screens
    • 9.5.1 Advantages of Stem Cell-Based Assays
    • 9.5.2 Stem Cell-Based Assay Companies
  • 9.6 Research, Reagents, and Other Non-Therapeutic Stem Cell Activities
  • 9.7 Drivers and Restraints

10. Qualitative Analysis of the Stem Cell Technologies and Applications Market 2018-2028

  • 10.1 SWOT Analysis of the Stem Cell Technologies and Applications Market
  • 10.2 Strengths
    • 10.2.1 HSCT is already an Established Procedure
    • 10.2.2 Approvals for Stem Cell Therapies
    • 10.2.3 Relaxation of Regulatory Barriers
  • 10.3 Weaknesses
    • 10.3.1 Phase 3 Trials only make up a Small Fraction of the Currently Ongoing Clinical Trials
    • 10.3.2 Uncertain Mechanisms of Action in Stem Cell Therapies
    • 10.3.3 Regulatory and Reimbursement Concerns
    • 10.3.4 The scare of a possible immune rejection after a stem cell transplant
  • 10.4 Opportunities
    • 10.4.1 Huge Potential in Unmet Clinical Needs
    • 10.4.2 Opportunities in the Non-Therapeutic Uses of Stem Cells, including Cord Blood Banking and Cell-Based Assays
    • 10.4.3 Interactions with Related Technologies will Offer new Opportunities
    • 10.4.4 Genetic Modification of Stem Cells
  • 10.5 Threats
    • 10.5.1 Financial Risks and Under-Capitalisation of the Stem Cells Sector
    • 10.5.2 Threat of Pipeline Failures
    • 10.5.3 Long-Term Safety Concerns
    • 10.6 STEP Analysis of the Stem Cell Technologies and Applications Market
  • 10.7 Social Factors
    • 10.7.1 Increasing Burden of Disease as World Population Ages
    • 10.7.2 Biological Insurance through Stem Cell Banking
    • 10.7.3 Stem Cell Tourism: Both an Opportunity and Threat to the Market
  • 10.8 Technological Factors
    • 10.8.1 Increasing Research Output
    • 10.8.2 IPSC Advances
    • 10.8.3 Greater Understanding of Stem Cell Differentiation
    • 10.8.4 Interactions with Other Technologies
    • 10.8.5 CRISPR: A Breakthrough in Genome Editing
  • 10.9 Economic Factors
    • 10.9.1 Grey Market for Stem Cell Therapies
    • 10.9.2 Broad Changes in Pharma / Healthcare Markets
    • 10.9.3 New Business Models are required due to the Unique Challenges Posed by these Non-Traditional Therapies
  • 10.10 Political Factors
    • 10.10.1 Controversies over Embryonic Stem Cell Research
    • 10.10.2 Support from National Governments
    • 10.10.3 Patient Pressure to Deregulate the Stem Cell Therapies Market

11. Conclusions

  • 11.1 Stem Cell Technologies and Applications: An Emerging Market
  • 11.2 Current Leading Segments and Regional Markets
  • 11.3 World Stem cell Technologies and Applications Market Forecast 2017-2028
  • 11.4 The Future of the Stem Cell Market
  • 11.5 Concluding Remarks

Appendices

  • Glossary
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 2.1 Classifying Stem Cells by Potency
  • Table 2.2 The Different Germ Layers and Their Associated Types of Cells and Organs
  • Table 2.3 Main Types of Stem Cells and Their Properties
  • Table 2.4 Stem Cell Donor Terminology
  • Table 2.5 The Different Phases of Clinical Trials
  • Table 3.1 NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2016 and 2017
  • Table 3.2 Estimated and expected NIH spending in Stem cell research from 2013-2018(expected) (in million USD)
  • Table 3.3 New FDA Draft Guidance's
  • Table 3.4 StemGen's Classifications of European Nations by Level of Permissiveness towards hESC research
  • Table 4.1 Stem Cell Technologies and Applications Market by Region: Revenues ($m), Market Shares (%), 2017
  • Table 4.2 Stem Cell Technologies and Applications Market by Segment: Revenues ($m), Market Shares (%), 2017
  • Table 4.3 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2022
  • Table 4.4 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 4.5 Stem Cell Technologies and Applications Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 4.6 Stem Cell Technologies and Applications Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 4.7 Stem Cell Technologies and Applications Market by Segment: Revenues ($m), Market Share (%), 2022 and 2028
  • Table 5.1 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 5.2 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2026
  • Table 5.3 Comparison of Bone Marrow, Peripheral Blood and Cord Blood for HSCT
  • Table 5.4 Estimated Number of HSCT Operations Performed Globally, by Donor Type: AGR (%), CAGR (%), 2015-2017
  • Table 5.5 European HSCT Operations: Number of Operations by Donor Type, 2011-2017
  • Table 5.6 Indications with Medicare Coverage for HSCT (both Autologous and Allogeneic)
  • Table 5.7 Malignancies and Other Haematological Diseases which may be Treated with HSCT
  • Table 5.8 HSCT-Addressable Cancers: Estimated Combined Incidence in the US, Japan and Western Europe (Number of Cases), CAGR (%), 2012-2024
  • Table 5.9 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2018
  • Table 5.10 Past and Present ProHema (Fate Therapeutics) Clinical Trials
  • Table 5.11 MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 5.12 MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 5.13 HSC835 (Novartis) Ongoing Clinical Trials, 2017
  • Table 6.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 6.2 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 6.3 Global Cardiovascular Disease Market by Drug Class: Revenue ($bn), 2017
  • Table 6.4 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), % of Total Deaths, Deaths per 100,000 Population, 2015 and 2030
  • Table 6.5 Advantages, disadvantages and different clinical trials that are ongoing
  • Table 6.6 Hearticellgram-AMI (Pharmicell) Sales Estimates: Revenue ($m), AGR (%), 2014-2017
  • Table 6.7 Hearticellgram-AMI Forecast (Pharmicell): Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 6.8 Hearticellgram-AMI Forecast (Pharmicell): Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 6.9 CardioRel (Reliance Life Sciences) Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 6.10 CardioRel (Reliance Life Sciences) Forecast: Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 6.11 Past and Present MultiStem (Athersys) Clinical Trials, 2018
  • Table 6.12 Ongoing Stemedica Cell Technologies Clinical Trials in Cardiovascular Indications, 2018
  • Table 7.1 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2022
  • Table 7.2 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 7.3 Ongoing MA09-hRPE (Ocata Therapeutics) Clinical Trials in SMD, 2018
  • Table 7.4 Ongoing MA09-hRPE (Ocata Therapeutics) Clinical Trials in AMD, 2015
  • Table 8.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 8.2 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 8.3 Osteocel Plus Forecast (NuVasive): Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 8.4 Osteocel Plus Forecast (NuVasive): Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 8.5 Trinity Evolution and Elite (Orthofix): Revenues ($m), AGR (%), CAGR (%), 2010-2014
  • Table 8.6 Trinity Evolution and Elite (Orthofix) Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 8.7 Trinity Evolution and Elite (Orthofix) Forecast: Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 8.8 CARTISTEM Revenues: Revenue ($m), AGR (%), 2013-H1 2015
  • Table 8.9 CARTISTEM (MEDIPOST) Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 8.10 CARTISTEM (MEDIPOST) Forecast: Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 8.11 Non-Oncologic Diseases which can be Treated with HSCT
  • Table 8.12 Processes and Mechanisms of Bone Repair
  • Table 8.13 Anterogen Clinical Trials, 2018
  • Table 8.14 PDA-002 (Celgene Corporation) Current Clinical Trials
  • Table 8.15 PNEUMOSTEM (MEDIPOST) Past and Present Clinical Trials
  • Table 8.16 Translational Biosciences Currently Open Clinical Trials, 2015
  • Table 8.17 S-Evans Biosciences Clinical Trials, 2015
  • Table 9.1 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2022
  • Table 9.2 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2023-2028
  • Table 9.3 Selected US Stem Cell Banks, 2018
  • Table 9.4 Selected Non-US Stem Cell Banks, 2017
  • Table 9.5. Prominent Dental Stem cell banks globally
  • Table 9.6 Selected Stem Cell Supply and Processing Companies
  • Table 9.7 Selected Companies with Involvement in Stem Cell-Based Assays, 2017
  • Table 10.1 World 65+ Population Forecast: Population (m), 2015-2050

List of Figures

  • Figure 1.1 Global Stem Cell Technologies and Applications Market Segmentation Overview, 2018
  • Figure 2.1 Timeline of Stem Cell Research
  • Figure 3.1 NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2017
  • Figure 3.2 NIH Spending for stem cell research by year (in USD billions)
  • Figure 3.3 CIRM Funding by Disease Area, Percentage (%), 2017
  • Figure 4.1 Therapeutic Applications of Stem Cells vs Non-Therapeutic Applications: Market Shares (%), 2017
  • Figure 4.2 Therapeutic Applications of Stem Cells vs Non-Therapeutic Applications: Market Shares (%), 2028
  • Figure 4.3 Stem Cell Technologies and Applications Market by Region: Market Shares (%), 2017
  • Figure 4.4 Stem Cell Technologies and Applications Market by Segment: Market Shares (%), 2017
  • Figure 4.5 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), 2017-2028
  • Figure 4.6 Stem Cell Technologies and Applications Market Forecast by Segment: Revenue ($m), 2017-2028
  • Figure 4.7 Stem Cell Technologies and Applications Market Forecast by Segment, 2017-2028
  • Figure 4.8 Stem Cell Technologies and Applications Market: Market Shares (%) by Segment, 2022
  • Figure 4.9 Stem Cell Technologies and Applications Market: Market Shares (%) by Segment, 2028
  • Figure 4.10 Stem Cell Technologies and Applications Market: Drivers and Restraints
  • Figure 5.1 Stem Cell Cancer Therapeutics Market Forecast: Revenue ($m), 2017-2028
  • Figure 5.2 Estimated Proportions of Global HSCT Operations by Donor Type, 2017
  • Figure 5.3 European HSCT Operations by Donor Type, 2011-2017
  • Figure 5.4. Estimated New Cases of Leukemia, Lymphoma and Myeloma in 2017
  • Figure 5.5. Estimated new cases of leukemia diagnosed in 2017
  • Figure 5.6 HSCT-Addressable Cancers: Estimated Combined Incidence in the US, Japan and Western Europe (Number of Cases), 2012-2024
  • Figure 5.7 Most Common Diseases Treated by Cord Blood from LifeCord: Percentage (%) 2017
  • Figure 5.8 MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenue ($m), 2017-2028
  • Figure 5.9 Stem Cell Cancer Therapeutics Market: Drivers and Restraints
  • Figure 6.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenue ($m), 2016-2028
  • Figure 6.2 Global Cardiovascular Disease Market by Drug Class: Market Shares (%), 2017
  • Figure 6.3 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions ), 2015 and 2030
  • Figure 6.4 Hearticellgram-AMI (Pharmicell) Sales Estimates: Revenue ($m), 2014-2017
  • Figure 6.5 Hearticellgram-AMI (Pharmicell) Forecast: Revenue ($m), 2017-2028
  • Figure 6.6 CardioRel (Reliance Life Sciences) Forecast: Revenue ($m), 2017-2028
  • Figure 6.7 Stem Cell Cardiovascular Therapeutics Market: Drivers and Restraints, 2016-2027
  • Figure 7.1 Stem Cell CNS Therapeutics Market Forecast: Revenue ($m), 2017-2028
  • Figure 7.2 Stem Cell CNS Therapeutics Market: Drivers and Restraints,
  • Figure 8.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m) 2018-2028
  • Figure 8.2 Osteocel Plus (NuVasive) Forecast: Revenue ($m), 2018-2028
  • Figure 8.3 Trinity Evolution and Elite (Orthofix): Revenue ($m), 2010-2014
  • Figure 8.4 Trinity Evolution and Elite (Orthofix): Revenue ($m), 2018-2028
  • Figure 8.5 CARTISTEM (MEDIPOST) Forecast: Revenues ($m) 2017-2028
  • Figure 9.1 Stem Cell Non-Therapeutic Applications Market Forecast: Revenue ($m), 2017-2028
  • Figure 9.2 Stem Cell Non-Therapeutic Applications Market: Drivers and Restraints
  • Figure 10.1 SWOT Analysis of the Stem Cell Technologies and Applications Market
  • Figure 10.2 STEP Analysis of the Stem Cell Technologies and Applications Market
  • Figure 10.3 World 65+ Population Forecast: Population (m), 2015-2050
  • Figure 12.1 Stem Cell Technologies and Applications Market Forecast, split by Therapeutic vs Non-Therapeutic Applications: Revenue ($m), 2017-2028

Companies Listed

  • Aastrom Biosciences
  • Advanced Cell Technology
  • Alder Biopharmaceuticals
  • Alkem
  • AllCells
  • Allergan
  • AlloSource
  • Americord
  • Americord
  • Amgen
  • Amgen
  • Angiocrine Bioscience
  • Angiocrine Bioscience
  • Anterogen
  • Anterogen
  • Apceth
  • Arteriocyte
  • Arteriocyte
  • Associated Press
  • Astellas Pharma
  • Asterias Biotherapeutics
  • Asterias Biotherapeutics
  • Athersys
  • Athersys
  • Auriga Ventures
  • Axiogenesis
  • Axiogenesis
  • Bank a Tooth
  • Baxter
  • Baxter Healthcare
  • BaYi Brain Hospital
  • BioCardia
  • BioCardia
  • BioE
  • BioE
  • BioEden
  • BioEden
  • Biogenea-Cellgenea
  • Bioheart, Inc.
  • Biologic Therapies
  • BioMet Orthopedics
  • Biosciences
  • BioTechnology
  • BioTime
  • BioTime Asia
  • Blackstone
  • Blackstone Medical
  • Bloodworks
  • Bluebird Bio
  • Brain Somatic Mosaicism
  • BrainStorm Cell Therapeutics
  • Caladrius Biosciences
  • California Institute for Regenerative Medicine (CIRM)
  • Calimmune
  • Capricor
  • Cardio3
  • Caribou
  • Carolinas Cord Blood Bank (CCBB)
  • Casey Eye Institute
  • Cedars-Sinai Heart Institute
  • Celgene
  • Cell Cure Neurosciences
  • Cell Research Groups
  • Cell Therapy Catapult
  • Cellartis
  • CellCentric
  • Cellectis
  • Cellerant Therapeutics
  • Cellerix
  • CELLTREE
  • Cellular Biomedicine Group (CBMG)
  • Cellular Dynamics International
  • Center for International Blood and Marrow Transplant Research (CIBMTR)
  • Centers for Medicare & Medicaid Services
  • Cephalon
  • Cesca Therapeutics
  • Ceylad
  • China Cord Blood Corporation
  • China Cord Blood Corporation
  • China Regenerative Medicine International Limited (CRMI)
  • Chugai Pharmaceutical Co. Ltd.
  • CJ CheilJedang
  • Clal Biotechnologies Industries
  • Cleveland Biolabs
  • Cleveland Cord Blood Center
  • ClinImmune Labs
  • Cochrane
  • Cognate BioServices
  • Cook General BioTechnology
  • Cord Blood America
  • Cordlife Group
  • CordVida
  • CRISPR Therapeutics
  • Cryo-Cell International
  • CryoCord
  • CryoHaldco
  • Cryonix CJSC
  • Cryo-Save
  • CryoViva
  • CXR Biosciences
  • Cytori Therapeutics
  • Denali Ventures
  • Dendreon
  • Dong-A Pharmaceuticals Co.
  • Dynamics
  • Elbit Imaging
  • Elbit Medical Technologies
  • Eli Lilly
  • EpiStem
  • ESI BIO
  • EuroStemCell
  • Fate Therapeutics
  • FDS Pharma
  • Fondazione Centro San Raffaele
  • Fondazione Telethon
  • Forbion Capital Partners
  • Forticell Bioscience
  • Future Health Biobank
  • Gamida Cell
  • Gemabank
  • Gene Cell International
  • Genetico
  • Genetrix Group
  • Geron Corporation
  • Gilead
  • GlobalStem
  • Globocan
  • GSK
  • Howard Hughes Medical Institute
  • Human Stem Cells Institute
  • ImmunoCellular Therapeutics
  • Immunovative Therapies
  • Indian Department of Biotechnology
  • Insception Biosciences
  • Intellia Therapeutics
  • IntelliCell Biosciences
  • IPS Academia Japan
  • Isar Medical Centre
  • Israel Healthcare Venture
  • Japan Institute of Biomedical Research.
  • JCR Pharmaceuticals
  • JingYuan Bio.
  • Johnson & Johnson
  • Kirby Institute
  • Lifebank Cryogenics
  • LifebankUSA
  • LifeCord
  • LifeMap Sciences
  • LifeMap Solutions
  • LifeSouth Community Blood Centers Inc
  • Lonza
  • Maxcyte
  • Mayo Clinic
  • MedCell Bioscience
  • MEDIPOST
  • Medistem Panama
  • Medistem Panama Inc.
  • Medtronic
  • Mesoblast
  • Miltenyi Biotec
  • National Dental Pulp laboratory
  • NeoStem
  • Neuralstem
  • New England Cord Blood Bank
  • New York Blood Center
  • Novartis
  • NovoCell
  • NurOwn
  • Nuvasive
  • Ocata Therapeutics
  • OncoCyte
  • Opexa Therapeutics
  • OrLife Bio
  • Orthofix
  • Osiris Therapeutics
  • Pahrump Valley Times
  • Pfizer
  • Pharmicell
  • Pharmsynthez
  • Plasticell
  • Pluristem Therapeutics
  • Polyphor
  • Precious Cell Group
  • Prix Galien
  • PsychENCODE
  • Pulp Laboratory
  • Q Therapeutics
  • Quest Biomedical
  • ReCyte Therapeutics
  • Ree Labs
  • Regenerative Sciences
  • Regenerex
  • Regeneron
  • Regeneus
  • Reliance Group
  • Reliance Life Sciences
  • ReNeuron
  • RepliCel Life Sciences
  • Reprobank
  • ReproCELL
  • RIKEN Center for Developmental Biology
  • Roche
  • Roslin Cellab
  • RTI Biologics
  • RTI Surgical
  • RUSNANO Corporation
  • RVC OJSC
  • SanBio
  • Sangamo BioSciences
  • Sanofi
  • S-Evans Biosciences
  • Spinesmith Partners
  • SSM Cardinal Glennon
  • SSM Cardinal Glennon Children's Medical Center
  • Stem Cell Bank
  • Stemade
  • Stemcell Technologies
  • StemCore
  • StemCyte
  • Stemedica Cell Technologies
  • StemGen
  • StemImmune Inc
  • Stemina Biomarker Discovery
  • StemSave
  • Store-a-tooth
  • SynBio
  • Systems
  • Takara Bio
  • Takeda
  • TAP Biosystems
  • Teva
  • The Zon Laboratory
  • TiGenix
  • Tong Yuan Stem Cell
  • Tooth Bank
  • TrakCel
  • Transcell Biologics Pvt Ltd.
  • Translational Biosciences
  • U.S. Stem Cell, Inc
  • UCL Business PLC
  • UCL Institute of Ophthalmology
  • UCLA
  • uniQure
  • US Stem Cell, Inc.
  • Valeant
  • VAULT Sc Inc.
  • Vericel Corporation
  • Vericel Corporation
  • Vesta Therapeutics
  • ViaCord
  • ViaCyte
  • ViroMed
  • Vita34
  • Vitro Biopharma
  • WA Optimum Health Care
  • WHO

List of Organisations Mentioned in the Report

  • American Academy of Neurology
  • American Academy of Pediatrics (AAP)
  • American Neurological Associates Annual Meeting
  • American Society of Blood and Marrow Transplantation.
  • Americas Committee for Treatment and Research in Multiple Sclerosis
  • Boston Children's Hospital
  • Cha General Hospital
  • China Food and Drug Administration (CFDA)
  • Chinese Academy of Sciences
  • Chinese Ministry of Health
  • Chinese Ministry of Science and Technology
  • Committee for Medicinal Products for Human Use (CHMP)
  • Consortium of Multiple Sclerosis Centers
  • Cord Blood Registry
  • Duke University School of Medicine
  • EMA
  • European Court of Human Rights
  • European Court of Justice
  • European Group for Blood and Marrow Transplantation (EBMT)
  • European Haematology Association
  • Federal D.C. Court of Appeals
  • Harvard Business School
  • Harvard Stem Cell Institute
  • Harvard University
  • Human Fertilisation and Embryology Authority (HFEA)
  • Human Tissue Authority
  • International Society for Stem Cell Research (ISSCR)
  • International Stem Cell Corporation (ISCO)
  • International Stemcell Services
  • Israel Stem Cell Society
  • Japan's Ministry of Economy, Trade and Industry (METI)
  • Japanese Health Ministry
  • Japanese Ministry of Labour and Welfare (MHLW)
  • Japanese Pharmaceuticals and Medical Devices Agency
  • Karolinska Institute
  • Korean Food and Drug Administration
  • Korean MFDS (Ministry of Food and Drug Safety)
  • Massachusetts General Hospital
  • McMaster University
  • Musculoskeletal Transplant Foundation (MTF)
  • New York Heart Association
  • NHS Blood and Transplant Authority
  • Northwestern University
  • Novartis Research Foundation
  • Oregon Health and Science University
  • Psychiatric Gene Networks
  • Queen Mary University of London
  • Tel Aviv University
  • The European Commission
  • The Marcus Foundation
  • UK Care Quality Commission
  • UK Department of Health
  • UK Department of Health and the Medical Research Council
  • UK Home Office
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • UK National Institute for Health Research
  • UK Regenerative Medicine Platform
  • United Nation's Department of Economic and Social Affairs
  • University of California
  • University of Colorado Anschutz Medical Campus (AMC)
  • University of Colorado Cord Blood Bank
  • University of Kyoto
  • University of Massachusetts
  • University of Washington
  • University of Western Ontario
  • University of Wisconsin Alumni Research Foundation
  • US Congress
  • US District Court for the District of Columbia
  • US FDA
  • US National Cord Blood Program
  • US National Institute of Allergy and Infectious Diseases (NIAID)
  • US National Institute of Health (NIH)
  • US Patent and Trademark Office
  • US Supreme Court
  • Yale University
Back to Top